Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totalling 30,600 shares, a drop of 28.2% from the March 31st total of 42,600 shares. Based on an average daily trading volume, of 27,700 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.8% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, April 1st. StockNews.com raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Friday, April 5th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Assembly Biosciences stock. Acuitas Investments LLC acquired a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 265,585 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Acuitas Investments LLC owned 0.40% of Assembly Biosciences at the end of the most recent reporting period. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Trading Down 5.3 %

NASDAQ:ASMB traded down $0.71 on Friday, hitting $12.65. The company’s stock had a trading volume of 29,550 shares, compared to its average volume of 17,185. Assembly Biosciences has a one year low of $7.69 and a one year high of $20.04. The firm has a market capitalization of $69.32 million, a P/E ratio of -0.74 and a beta of 0.57. The stock has a fifty day moving average of $13.07 and a two-hundred day moving average of $11.05.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.